CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC 50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > Histone Demethylase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.